Depending on the type of Eczema, its exact cause of is not yet known. However, atopic dermatitis is believed to be related to malfunction of the body’s immune system. Like asthma and hay fever, atopic dermatitis may ultimately be caused by an immune system overreaction that creates an allergic response to common irritants. Futher clinical research into the cause of Eczema are ongoing.
What is Eczema?
czema, also known as atopic dermatitis, is an itchy inflammation of the upper layers of skin. It is very common, affecting up to 35 million Americans with more than 3 million new cases per year. It presents a red, scaly, itchy rash that is easily mistaken for other skin conditions.
Symptoms are usually most noticeable on the arms and behind the knees. However, eczema can appear anywhere throughout the body. The cracked, rough skin affected by the condition can sometimes develop painful blisters.
What Causes Eczema?
What are the Different Types of Eczema?
How is Eczema Diagnosed?
About 10% to 20% of infants and 3% of children and adults in the United States have eczema. Overall, about 10% of people have some form of eczema. At any age, the majority of people who present symptoms of eczema have had the condition since very early in life.
Most infants will outgrow the condition, but not all.
To diagnose eczema, a doctor will look at family history. Families with an existing history of eczema, allergies, asthma, or defects in the skin barrier are more likely to see cases of eczema. No lab tests are needed, but a skin patch test is used to rule out other conditions.
How is Eczema Treated or Cured?
The majority of eczema patients will experience periodic flare-ups of the condition. Between these flare-ups, the condition may be asymptomatic – that is, patients will not experience any discomfort. Eczema is not contagious, so these periods are uneventful. With Eczema being a condition affecting a large number of individuals, a wide array of clinical trials are ongoing.
During eczema flare-ups, a doctor may recommend many types of treatment to reduce symptoms. The most common is medicated cream that reduces the itching and repairs damage to affected skin. Over time, patients learn which medication is best for them.
Eczema can be compounded by a bacterial infection from the open cracks or sores in the skin. In this case, antibacterial medication must be used to fight infection. In severe flare-ups, oral corticosteroids are recommended to reduce the body’s inflammation response.
An appropriate course of proactive treatment significantly reduces the complications and the discomfort associated with eczema. Although new treatments have shown promise, there is no cure for the condition.
Eczema Clinical Trials
The following clinical trial are the most up to date provided by Clinicaltrials.gov. If you would like us to feature some additional trials, please feel free to notify our team.
ClinicalTrials.gov: Recruiting Studies | eczema | Last update posted in the last 300 days Studies found on ClinicalTrials.gov by a search of: Recruiting Studies | eczema | Last update posted in the last 300 days
Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD
on April 9, 2020 at 4:00 pm
Condition: Atopic DermatitisInterventions: Drug: ATx201; Drug: ATx201 OINTMENT vehicleSponsor: UNION therapeuticsRecruiting
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
on March 18, 2020 at 4:00 pm
Condition: Atopic DermatitisInterventions: Drug: 1.1% w/w AMTX-100 CF; Drug: 0.33% w/w AMTX-100 CF; Drug: 0.11% w/w AMTX-100 CF; Drug: PlaceboSponsors: Amytrx Therapeutics, Inc.; Amarex Clinical ResearchRecruiting
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
on March 13, 2020 at 4:00 pm
Condition: Atopic DermatitisIntervention: Drug: ZEP-3NaSponsor: Shulov Innovate for Science Ltd. 2012Recruiting
The Effectiveness of Antibacterial Therapeutic Clothing Based on Silver or Chitosan as Compared With Non-antibacterial Therapeutic Clothing in Patients With Moderate to Severe Atopic Dermatitis
on March 5, 2020 at 5:00 pm
Condition: Atopic DermatitisInterventions: Device: DermaCura® Chitosan based antimicrobial therapeutic clothing; Device: Binamed® silver based antimicrobial therapeutic clothing; Device: Binamed® therapeutic clothing without antimicrobial agentsSponsors: Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); UMC Utrecht; St. Antonius Hospital; ZonMw: The Netherlands Organisation for Health Research and Development; BAP Medical; D&M B.V.; DeclaCare; University Medical Center GroningenRecruiting
Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment
on February 19, 2020 at 5:00 pm
Condition: Atopic DermatitisIntervention: Sponsors: UMC Utrecht; SanofiRecruiting
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
on February 17, 2020 at 5:00 pm
Condition: Atopic DermatitisInterventions: Drug: RPT193; Drug: PlaceboSponsor: RAPT Therapeutics, Inc.Recruiting
Topical L. Reuteri in Children With Atopic Dermatitis
on February 12, 2020 at 5:00 pm
Condition: Atopic DermatitisIntervention: Other: Topical L. reeuteriSponsors: Innovacion y Desarrollo de Estrategias en Salud; BioGaia ABRecruiting
A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)
on February 10, 2020 at 5:00 pm
Condition: Atopic DermatitisInterventions: Device: Wrist Actigraphy Device; Device: Sleep HeadbandSponsor: AbbVieRecruiting
Prospective Longitudinal Observational Research in Atopic Dermatitis
on January 27, 2020 at 5:00 pm
Conditions: Https://Meshb.Nlm.Nih.Gov/Record/ui?ui=D003876; Atopic Dermatitis; Asthma; Atopic Dermatitis and Related ConditionsIntervention: Sponsors: University of Zurich; University of BonnRecruiting
Pre-SunBeam TEWL AUC
on January 13, 2020 at 5:00 pm
Condition: Atopic DermatitisInterventions: Device: GPSkin Barrier Pro; Device: Aquaflux AF200Sponsors: Northwestern University; National Jewish Health; National Institute of Allergy and Infectious Diseases (NIAID)Recruiting
The Factors Affecting Atopic Dermatitis in Children Age 1-3
on January 6, 2020 at 5:00 pm
Condition: Atopic DermatitisIntervention: Sponsor: Akusherstvo ProRecruiting
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
on January 2, 2020 at 5:00 pm
Condition: Atopic DermatitisIntervention: Drug: Crisaborole 2% Top OintSponsors: Massachusetts General Hospital; PfizerRecruiting
A Pilot Study to Explore the Role of Gut Flora in Eczema
on January 2, 2020 at 5:00 pm
Condition: EczemaIntervention: Other: No InterventionSponsor: ProgenaBiomeRecruiting
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
on December 26, 2019 at 5:00 pm
Condition: Atopic DermatitisInterventions: Drug: MEDI3506; Drug: PlaceboSponsor: AstraZenecaRecruiting
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
on December 26, 2019 at 5:00 pm
Condition: Atopic DermatitisInterventions: Drug: DS-2741a; Drug: PlaceboSponsor: Daiichi Sankyo Co., Ltd.Recruiting
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
on December 12, 2019 at 5:00 pm
Condition: Atopic DermatitisIntervention: Drug: UpadacitinibSponsor: AbbVieRecruiting
Sensory Nociceptive Nerve Fibers, Key Regulator of Immune Response Type 2 in Atopic Dermatitis
on December 10, 2019 at 5:00 pm
Condition: Atopic DermatitisInterventions: Other: Clinical examination; Procedure: Biopsies; Other: Blood testSponsor: University Hospital, ToulouseRecruiting
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
on December 10, 2019 at 5:00 pm
Condition: Atopic DermatitisIntervention: Drug: J. lividumSponsor: DermBiont, Inc.Recruiting
Early Origins of Allergy and Asthma
on December 5, 2019 at 5:00 pm
Conditions: Allergy; Asthma; Food Allergy; Allergic Sensitisation; Atopic DermatitisIntervention: Sponsors: Pontificia Universidad Catolica de Chile; University of Chile; Comisión Nacional de Investigación Científica y TecnológicaRecruiting
Skin Tape Transcriptome Methods in Children
on November 27, 2019 at 5:00 pm
Condition: Atopic DermatitisIntervention: Other: Skin tape stripsSponsor: National Jewish HealthRecruiting
Patients coping with a new eczema diagnosis or long-term eczema symptoms may be able to reduce flare-ups by learning about what worsens their condition. As with conventional allergies, many different environmental stressors can trigger a flare-up.
After a diagnosis, it is a good idea to keep a symptom journal. Patients should list out symptoms, when and where they occurred, and if there were any factors that might have contributed. Over time, it can become much easier to notice and avoid eczema triggers.
Food is among the most common eczema trigger. Some people experience heavy symptoms after exposure to nuts or dairy. It isn’t necessary to consume these foods to have symptoms: Just touching them can be enough. Dietary triggers should be eliminated entirely.
Certain soaps, detergents, and shampoos are common triggers. Patients should be especially careful about commercial antibacterial hand soap. Since bacteria can also exacerbate symptoms, it is important to find bathroom soaps that do not contribute to symptoms.
Eczema may be sensitive to extreme humidity or hot or cold temperatures. This causes eczema in some people to have a seasonal cycle. No matter the time of year, stress can make symptoms worse.